Trial Profile
A case control study to evaluate the efficacy of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in patients with Liver Transplant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- 06 May 2017 New trial record
- 03 May 2017 Results presented at the 2017 American Transplant Congress